Frontiers in Psychiatry
February 21, 2020
Max Wolff, Ricarda Evens, Lea J. Mertens et al.
188 citations
A conceptual model proposes that psychedelic-assisted therapies reduce experiential avoidance and increase acceptance through mechanisms similar to those in cognitive behavioral therapy. In controlled clinical settings, psychedelics relax avoidance-related beliefs, boosting motivation for acceptance via operant conditioning. This allows relatively avoidance-free exposure to intensified private events, where relaxed beliefs encounter corrective information and become revised. Such belief revision may explain lasting increases in acceptance and decreases in psychopathology. The article outlines open research questions and clinical implications.
Progress in neuro-psychopharmacology & biological psychiatry
February 2, 2018
Simon Reiche, Leo Hermle, Stefan Gutwinski et al.
125 citations
Anxiety and depression are common in people with life-threatening diseases, harming quality of life and prognosis. Serotonergic hallucinogens like LSD and psilocybin were first studied in the 1960s, and interest has recently revived. A systematic review of clinical trials from 1960 to 2017 identified 11 eligible trials with 445 participants: 7 on LSD (323 participants), 3 on psilocybin (92), and 1 on DPT (30). Four more recent randomized controlled trials (104 participants) had higher methodological quality than earlier studies. Evidence supports that these substances reduce anxiety and depression in patients with life-threatening diseases, with anecdotal reports of improved quality of life and reduced fear of death. Side effects were low in studies following safety guidelines.
Journal of Psychoactive Drugs
October 24, 2019
Toby Lea, Nicole Amada, Henrik Jungaberle
121 citations
People are self-administering very low doses of psychedelic drugs, known as microdosing, to improve mental health, wellbeing, and cognitive function, but little research has been conducted. A content analysis of Reddit discussions examined motivations, dosing practices, and perceived benefits and limitations. Motivations included managing mental health issues, improving psychosocial wellbeing, and cognitive enhancement. Self-reported benefits included cognitive and creative enhancement, reduced depression and anxiety, enhanced self-insight, improved mood, and better social interactions. Limitations included dosing problems, adverse physical effects, taking illegal substances, limited or no improvement, increased anxiety, and concerns about dependence. Standard doses in therapeutic settings show potential for treating mental health conditions, but clinical research on microdosing is needed.
International Journal of Drug Policy
November 25, 2019
Toby Lea, Nicole Amada, Henrik Jungaberle et al.
119 citations
No Summary
The Lancet Psychiatry
December 12, 2023
Gerhard Gründer, Manuela Brand, Lea J. Mertens et al.
103 citations
No Summary
Neuroscience Applied
January 1, 2022
Lea J. Mertens, Michael Koslowski, Felix Betzler et al.
40 citations
Clinical trials with psychedelics like psilocybin face unique methodological challenges, particularly the difficulty of maintaining blinding due to the substances' pronounced subjective effects, which raises risks of expectation bias and nocebo effects. A phase II randomized, double-blind, active placebo-controlled parallel group trial with 144 patients is underway to evaluate psilocybin's efficacy and safety in treatment-resistant major depression. The trial, called EPIsoDE, is funded by the German Federal Ministry of Education and Research and addresses these challenges in its design.
Journal of Psychopharmacology
May 1, 2024
Max Wolff, Ricarda Evens, Lea J. Mertens et al.
34 citations
A new questionnaire, the General Change Mechanisms Questionnaire (GCMQ), reliably measures five psychotherapy processes—resource activation, therapeutic relationship, problem actuation, clarification, and mastery—during psychedelic experiences. Validated in 1153 English-speaking and 714 German-speaking users, the GCMQ showed good internal consistency and convergent validity. Experiences varied with setting and use motives (therapeutic, hedonic, escapist). Resource activation, clarification, and mastery moderated the link between stressful life events and well-being, suggesting potential therapeutic benefits. Five distinct user profiles emerged, which may inform clinical use and harm reduction.
Pharmacopsychiatry
May 12, 2021
Gerhard Gründer, Henrik Jungaberle
32 citations
Serotonergic psychedelics like psilocybin, LSD, and DMT, along with MDMA and ketamine, are among the most promising new treatments in psychiatry. Psychedelic-assisted psychotherapy requires redefining psychotherapeutic processes and embedding drug interventions in a new treatment infrastructure. Key challenges for practice and research include informed patient referral, screening, dosing preparation, assisted dosing sessions, psychological integration, and supporting patient communities. Defining treatment delivery infrastructures and therapist training requirements are further challenges. Implementation in routine mental health care must include public communication about the potential and risks. This paper provides a synopsis of challenges for practitioners, researchers, and regulators in the approval processes.
Anthropology of Consciousness
August 23, 2010
Janine Tatjana Schmid, Henrik Jungaberle, Rolf Verres
25 citations
Ayahuasca, a psychoactive beverage used in ritualized settings such as Santo Daime and neo-shamanic rituals, is often called a 'healing ritual' by participants. Interviews with 15 people who used ayahuasca for conditions like chronic pain, cancer, asthma, depression, alcohol abuse, or Hepatitis C revealed diverse motivations, subjective effects, and user types. Most participants believed ayahuasca positively influenced their illness or improved their coping, and enhanced their general well-being. The authors conclude that ayahuasca's effects should not be reduced to a pharmacological model; instead, it acts as a psychological catalyst shaped by sociocultural ideas.
Fortschritte der Neurologie · Psychiatrie
July 1, 2017
Tomislav Majić, Henrik Jungaberle, Timo Torsten Schmidt et al.
10 citations
The use of serotonergic hallucinogens (psychedelics) such as LSD and psilocybin, and entactogens such as MDMA, in psychotherapy has recently gained increasing scientific interest. This review summarizes current evidence on substance-assisted psychotherapy with serotonergic psychoactive substances. A selective literature search in PubMed and the Cochrane Library identified studies since 2000 examining these substances in psychotherapy. Indications studied include alcohol dependence (LSD and psilocybin), nicotine dependence (psilocybin), anxiety and depression in life-threatening physical illness (LSD and psilocybin), obsessive-compulsive disorder (psilocybin), treatment-resistant major depression (psilocybin), and post-traumatic stress disorder (MDMA). Dependence disorders, PTSD, and anxiety and depression in life-threatening physical illness are the best-evaluated indications. Evidence suggests efficacy with relatively good tolerability, but further studies are needed to assess these substances as future options for certain treatment-resistant mental disorders.
General hospital psychiatry
January 1, 2025
Max Wolff, Hans Rutrecht, Gerhard Gründer et al.
9 citations
As psychedelic treatments move from research settings into hospitals, clinics, and community practices, a new competencies framework outlines the skills needed for safe, effective, and ethically sound therapy. The framework is substance-unspecific and transtheoretical, covering foundational domains including psychotherapy, biomedicine, philosophy, socio-cultural awareness, existential concerns, legal issues, and self-experience. It translates these into practical competencies for multi-professional cooperation, screening, preparation, dosing, integration, and harm-reduction. Developed within the MIND Foundation's Augmented Psychotherapy Training program, the framework awaits systematic evaluation but offers an initial blueprint for future accredited certification and clinician training as these treatments enter mainstream care.
Journal of Psychoactive Drugs
March 6, 2019
Ansgar Rougemont-Bücking, Henrik Jungaberle, Milan Scheidegger et al.
6 citations
Among 4,475 young adult men in Switzerland, those who used psychedelics in the past year showed no significant difference in mental health (depressive symptoms, overall mental health, perceived stress, life satisfaction) compared to those who used no drugs. In contrast, users of MDMA, psychostimulants, and cannabis had poorer mental health. These effects were influenced by stressful life events and past family functioning. The findings suggest that some men may use substances to cope with life adversity, and the lack of a negative mental health association with psychedelics warrants further research in both men and women.
Fortschritte der Neurologie · Psychiatrie
June 20, 2022
Christopher W. Schmidt, Max Wolff, Gerhard Gründer et al.
5 citations
A survey of 530 psychiatrists and psychotherapists found divided opinions about psilocybin and psilocybin-assisted therapies. Many respondents considered psilocybin promising for treating mental disorders, with a majority viewing it as promising for depression. Greater knowledge about psilocybin was linked to more optimistic views about its therapeutic use. Providing additional scientific information about current research partly led to more favorable attitudes. As scientific and public discourse on psilocybin grows, shifts in psychotherapists' and psychiatrists' attitudes are expected.
Zeitschrift für Medizinische Psychologie
August 1, 2011
Lisa Fiedler, Henrik Jungaberle, Rolf Verres
4 citations
Members of the Santo Daime Church in the Netherlands primarily use ayahuasca for religious or spiritual reasons, as well as for medicinal-psychotherapeutic self-treatment. Among 21 participants interviewed over a longitudinal study (2003–2012), 20 showed these motives. Other important reasons included the desire for social interaction (16 participants) and seeking new or extraordinary experiences (17 participants). Hedonistic motives, performance enhancement, or underlying pathologies were negligible. The findings indicate that reasons for ayahuasca use are diverse and not limited to addiction.
Deutsches Ärzteblatt international
December 16, 2024
Moritz Spangemacher, Andrea Jungaberle, Henrik Jungaberle et al.
3 citations
Psilocybin treatment works differently from standard psychiatric medication, potentially offering rapid and lasting benefits across multiple diagnoses. It may improve not just symptoms but broader aspects of mental health, suggesting it could modify the underlying disease process and promote well-being. Psychedelic-assisted psychotherapy might become the first disease-modifying treatment in psychiatry.
Der Nervenarzt
February 12, 2025
Nina Hartter, Marvin Däumichen, Christopher Schmidt et al.
1 citation
An online survey of 1,456 mental health experts, patients, and the general public found that greater knowledge about psilocybin-assisted therapy (PAT), self-assessed knowledge, personal treatment experience, and prior experience with psychedelics predicted more positive attitudes toward introducing PAT. Providing information about PAT's potential only increased acceptance when combined with information about its risks. Participants were generally optimistic about implementing PAT. The link between knowledge and acceptance was confirmed, suggesting that balanced education and reporting on PAT can foster higher acceptance.
Psychotherapy and psychosomatics
May 27, 2026
Lea J Mertens, Felix Betzler, Manuela Brand et al.
A single 25 mg dose of psilocybin, or two such doses given six weeks apart, combined with psychotherapy produced a stable and clinically meaningful reduction in depression symptoms for up to twelve months in people with treatment-resistant depression. The average improvement on the Hamilton Rating Scale for Depression was about 7.9 points at six months and 7.7 points at twelve months, with no significant difference between dosing groups. Restarting standard antidepressant medication during follow-up was strongly linked to higher depression scores. This naturalistic follow-up of a phase 2b trial is the largest and most complete long-term assessment of psilocybin for depression to date.